You are here
Home > Drugs > FETZIMA ® (levomilnacipran) extended

Feel free to use our complete database with charts, tables and examples.

Clinical pharmacology

 FETZIMA ® (levomilnacipran) extended-release capsules, for oral use
[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

Initial U.S. Approval:  2013

Mechanism of Action: The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Indications and usage 

FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) .

Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established

Dosage and administration 

[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

How supplied

HOW SUPPLIED: Extended-release capsules: 20 mg, 40 mg, 80 mg and 120 mg

Reference

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.

FETZIMA ® (levomilnacipran) extended